Core Insights - Elanco Animal Health has announced label expansions for its canine prescription parasiticides, Credelio Quattro and Credelio, to include prevention of Lyme disease and protection against the longhorned tick [1][6][11] Group 1: Product Expansion and Efficacy - The expanded labels for Credelio Quattro and Credelio now include claims for the prevention of Lyme disease in dogs by killing black-legged ticks (Ixodes scapularis) [2][6] - Both products demonstrated 100% efficacy against the longhorned tick (Haemaphysalis longicornis) within 48 hours after infestation, continuing throughout the month [5][6] - The active ingredient lotilaner in both products is effective against various tick species, including the lone star tick (Amblyomma americanum), which is known for its association with alpha-gal syndrome in humans [7][9] Group 2: Market Context and Health Concerns - There have been over 422,000 cases of Lyme disease in dogs reported this year, surpassing the total annual cases of 2019, with northeast states being particularly affected [3][6] - The Companion Animal and Parasite Council (CAPC) has noted a significant rise in canine Lyme disease cases, emphasizing the need for effective parasite protection [4][6] - The longhorned tick is an invasive species now present in 22 states, posing a significant health risk to both animals and humans due to its ability to transmit various pathogens [4][6][5] Group 3: Company Commitment and Vision - Elanco emphasizes its commitment to innovation and scientific excellence, continuously working to address emerging threats in animal health [2][8] - The company aims to provide comprehensive protection for pets, enhancing the health and well-being of dogs through its expanded product offerings [7][8]